Physician profile
Matthew E Raecker
NPI 1548581374
$3,080.57
in general payments reported to CMS, 2019-2025
24 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $174 · 2021: $413 · 2022: $302 · 2023: $445 · 2024: $966 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $740.47 | 2019-2025 | Clareon, Argos, Eysuvis |
| Abbvie INC. | $336.91 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $250.68 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $244.95 | 2022-2024 | Acthar |
| Allergan, INC. | $241.51 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $189.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $159.93 | 2019-2023 | |
| The Cameron-Ehlen Group, INC. | $139.70 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $109.47 | 2022-2025 | Xiidra, Miebo, Sofport Ao |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $87.46 | 2019-2021 | |
| Horizon Therapeutics Plc | $77.90 | 2021-2023 | Tepezza |
| Biotissue Holdings INC. | $66.22 | 2022-2025 | |
| Rxsight INC | $58.63 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $57.38 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $49.56 | 2022-2023 | Rayone Spheric, Omidria, Rayone Emv |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.38 | 2024-2025 | Tepezza |
| Dompe US, INC. | $40.24 | 2025 | Oxervate |
| Omeros Corporation | $35.85 | 2019-2021 | |
| Glaukos Corporation | $35.20 | 2021 | |
| Sight Sciences, INC. | $31.27 | 2021-2022 | |
| Alimera Sciences, INC. | $26.88 | 2024 | Iluvien, Yutiq |
| Oyster Point Pharma, INC. | $26.80 | 2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $13.14 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Raecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.